MBXBF Stock UPDATES Microbix Biosystems (MBXBF) 0.4210 08/29/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Microbix Biosystems (MBXBF) 0.4210 $MBXBF

IIROC Trade Resumption - Microbix Biosystems Inc.
Newsfile Corp - Fri Aug 22, 12:57PM CDT
Trading resumes in:

IIROC Trade Halt - Microbix Biosystems Inc.
Newsfile Corp - Fri Aug 22, 12:17PM CDT
The following issues have been halted by IIROC:

eResearch Posts Update Report on Microbix Biosystems Inc.
ACCESSWIRE - Wed Feb 26, 1:52PM CST
Microbix Biosystems Inc. focuses on developing and commercializing biological products and technologies through leveraging its Core Base Business of developing infectious disease antigens (virology) for sale to large diagnostic kit manufacturers.

eResearch Posts Perspective on Microbix Biosystems Inc.
ACCESSWIRE - Mon Jan 27, 6:27AM CST
Microbix Biosystems Inc. focuses on developing and commercializing biological products and technologies through leveraging its Core Base Business of developing infectious disease antigens (virology) for sale to large diagnostic kit manufacturers.

IIROC Trading Halt / Suspension de la négociation par l'OCRCVM - Microbix Biosystems Inc., MBX
Marketwire Canada - Thu Jan 23, 11:49AM CST
Trading resumes in / Reprise des negociations pour :

Competitor Analysis: Thrombolytics & Fibrinolytics
M2 - Mon May 20, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j3c6qc/competitor) has announced the addition of the "Competitor Analysis: Thrombolytics & Fibrinolytics" report to their offering. The Competitive Intelligence Report Thrombolytics & Fibrinolytics as of May 2013 provides a competitor analysis in the product portfolios and development pipelines of novel thrombolytics and fibrinolytics for treatment of cardiovascular thrombosis, stroke and eye diseases. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report provides information on the various generation of marketed thrombolytics and includes a compilation of current active projects in research and development of novel thrombolytics and fibrinolytics including those in development in ophthalmology and in less regulated markets. In addition, the report lists company-specific product portfolios and R&D pipelines of thrombolytics and fibrinolytics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Examples of Companies Mentioned - Actavis - Alcon - Astellas Pharma - Bharat Biotech - Biocon - BioGeneric Pharma - Cadila Pharma - Cerbios Pharma - Cerevast Therapeutics - CSL Behring - Dexa Medica - Eisai - Ekos Corp - Grifols - Heber Biotec - Kedrion - Kee Pharma - Lundbeck - Microbix Biosystems - Mitsubishi Tanabe Pharma - Nanogen Biopharmaceuticals - ProteomTech - Pulse Therapeutics - Roche (Genentech) - Shantha Biotechnics (Sanofi) - Techpool BioPharma - Thrombogenics - Zydus Cadila For more information visit http://www.researchandmarkets.com/research/j3c6qc/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Microbix reports fiscal 2013 first quarter results
CNW Group - Thu Feb 14, 6:30AM CST
Company Provides Update on Product Pipeline

Microbix Sells Purified Water Business
CNW Group - Fri Feb 01, 6:30AM CST
Microbix Biosystems Inc. (TSX: MBX), a biotechnology company developing innovative biological products and technologies, today announced it has sold its Water-for-Injection business to Irvine Scientific in California. The sale was constructed on an earn-out basis, though specific deal terms were not disclosed.

Microbix' LumiSort Patent Upheld in U.S.
CNW Group - Fri Jan 25, 6:25AM CST
Sexing Technologies fails in second attempt to invalidate claims

Microbix Refiles Financial Statements
CNW Group - Thu Jan 10, 4:41PM CST
Microbix Biosystems Inc. (TSX:MBX) today refiled its financial statements for the year ended September 30, 2012 to correct two oversights in the Consolidated Statements of Comprehensive Loss.

Microbix Reports 15% Increase In Virology Product Sales In 2012
CNW Group - Fri Dec 28, 10:33PM CST
Urokinase, Vaccine Venture, and LumiSort Update




Scroll down for more posts ▼

Top 10 Most Recent News Articles

BASIS Bellevue Expands with New K-4 Campus

Updated Category News Views 89

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

Continue Reading
Yellow River Basin Firms Focus on Global Expansion

Updated Category News Views 58

Shandong's Bold Move on the Global Stage Imagine the bustling city of Jinan, Shandong's capital, humming with the energy of ambitious enterprises ready to leap into the global arena. That's exactly what unfolded at the conference aimed at forging international ties under the Belt and Road Initiative (BRI). For those out of the loop, this ain't just another business...

Continue Reading
H.R. 10549: Hope Charities Pushes for Pharmacy Freedom

Updated Category News Views 73

Hope Charities Takes a Stand for Patients In Prairieville, Hope Charities is throwing its weight behind a bill they believe is brewing up a patient revolution. The Patients Choice in Specialty Pharmacy Act, otherwise known as H.R. 10549, sparked by Representatives Neal Dunn and Joe Wilson, tackles the comfortable partnerships some insurers have been enjoying with their...

Continue Reading
Smirnoff Launches Marvel Event with $12.99 Offer

Updated Category News Views 114

Smirnoff's Bold Move to Ride Marvel's Coattails Here we are, watching a vodka brand hitch its wagon to a Hollywood juggernaut. Smirnoff has announced a fan experience to toast Marvel Studios' "Avengers: Doomsday." Of course, this isn't just about clinking glasses; it's a marketing stunt dressed in superhero tights. The impressive part? They’re selling the razzmatazz for...

Continue Reading
Markel Stays the Course: Solid Q3 Results in 2026

Updated Category News Views 141

Markel Group's Steady Climb Doesn't Falter Diving right into it, Markel Group's latest figures prove they're not just treading water. The insurance giant, trading under NYSE:MKL, reported solid third quarter results for 2026. And while some numbers might not be breaking records, they sure paint a picture of a company that's weathering the market with some grit. The...

Continue Reading
JumpCloud Tackles Compliance in the AI Era

Updated Category News Views 110

Compliance in a Changing Tech Landscape JumpCloud's stepping up in this brave new world riddled with tech and AI agents. They've got fresh platform features in their arsenal that'll keep organizations audit-ready day in and day out. Now, if you think compliance is just for the accountants to fret over, think again. In the agentic era, these advanced marvels—AI agents...

Continue Reading
Photocure's Q3 2026: Revenue Plateau and CFO Shakeup

Updated Category News Views 111

The Bladder Cancer Scene: Steady as She Goes Sometimes, you look at numbers and find tranquility, like staring into still waters. That's the scene over at Photocure ASA with their latest Q3 results. Clocking in with revenues of NOK 134.2 million from their Hexvix®/Cysview® products, they're barely flinching from last year's NOK 134.1 million. Is it a victory or a...

Continue Reading
Jamaica's Tourism Rebounds Post-Hurricane Challenges

Updated Category News Views 128

Weathering the Storm: A New Chapter for Jamaica It's been nearly a year since Hurricane Melissa hit, and Jamaica is proving that it won't be pushed around by nature's whims. The island's tourism industry, once battered, is now showing remarkable resilience. With hotels and villas reopening and shaking off the dust, it's safe to say Jamaica is back on its feet, and it's...

Continue Reading
Aker BP's Q3 2026: Strong Earnings Fuel Optimism

Updated Category News Views 25

Third Quarter Overview: Riding the Wave Aker BP's third quarter report is a raucous symphony of successes that have the market nodding in admiration. Marking significant strides with their offshore projects, the company seems to be in a cavalier mood as it boasts higher sales volumes and promising financials. Net production came in at 374 mboepd, dampened slightly by...

Continue Reading
Fidelis Care Opens $120K Workforce Grants for Aid

Updated Category News Views 112

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...

Continue Reading

Top 5 Most Recently Viewed Articles

Renault Achieves 1.3% Sales Growth Amid Market Challenges

Updated Category News Views 325

Renault Reports Sales Growth of 1.3% in 2024 French automaker Renault has announced a modest yet significant sales increase of 1.3% for the year 2024. This growth is particularly noteworthy given the challenging automotive market conditions that have been witnessed globally. Renault’s performance in the fourth quarter was particularly strong, aided by new vehicle...

Continue Reading
Economy Insights: Charlie Munger’s Vision for Retail Market’s Future

Updated Category News Views 303

Understanding Munger's Predictions Charlie Munger, the legendary vice chairman of Berkshire Hathaway, offered profound insights into the evolving retail landscape long before changes became evident in store closures and consumer habits. His vision emphasized a decisive division between high-end luxury markets and budget-friendly retailers, leaving little room for...

Continue Reading
Market Reaction: Anticipation Builds for Jobs Data Release

Updated Category News Views 112

Market Overview and Futures Decline U.S. stock index futures have taken a hit, driven by expectations surrounding important jobs data that could greatly influence the Federal Reserve's upcoming decisions on interest rates. Investors are particularly focused on the forthcoming nonfarm payrolls report, which serves as a key indicator of economic health and is set to be...

Continue Reading
Forecasting AI Growth: A $237.4 Billion Market Expansion

Updated Category News Views 274

The Dynamic Growth of Artificial Intelligence Market The artificial intelligence (AI) market is on the verge of transformative growth, projected to expand by USD 237.4 billion from 2024 to 2028. This surge is anticipated as the market develops at a compound annual growth rate (CAGR) of 30.07% during the forecast period. AI's increasing implementation across various...

Continue Reading
ASP Isotopes Inc. Announces Major Public Stock Offering

Updated Category News Views 78

ASP Isotopes Inc. Launches Public Offering ASP Isotopes Inc. (NASDAQ:ASPI) has initiated a public offering of its common stock, aiming to bolster its operational capabilities. This development marks a significant step for the company as it continues to explore avenues for growth in the advanced materials sector. Details of the Public Offering The offering includes a...

Continue Reading